Watch Ticker

Galecto, Inc. Common Stock

Go to Galecto, Inc. Common Stock Website

$0.70

(%)

Live

Previous Close

$0.7001

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$19.0 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Galecto, Inc. - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma

Related tickers: GLTO.

Read Full Article

Zacks Equity Research - Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Related tickers: GLTO.

Read Full Article

Trending Tickers

LASE

XNAS

$2.04

(%)

PACW

XNAS

$7.54

(%)

SMFL

XNAS

$3.58

(%)

XNYS

$69.47

(%)

MLGO

XNAS

$0.00

(%)